Publicacións en colaboración con investigadores/as de Eli Lilly and Company (15)

2013

  1. Treatment, outcomes, costs, and quality of life of women and men with acute coronary syndromes who have undergone Percutaneous coronary intervention: Results from the Antiplatelet Therapy Observational Registry

    Postgraduate Medicine, Vol. 125, Núm. 2, pp. 100-107

2012

  1. Clinical outcomes, resource use, and costs at 1 year in patients with acute coronary syndrome undergoing PCI: Results from the multinational APTOR registry

    Journal of Interventional Cardiology, Vol. 25, Núm. 1, pp. 19-27

2011

  1. International data on supportive therapies at 1 year in acute coronary syndrome patients undergoing PCI: Results from the APTOR study

    European Journal of Cardiovascular Prevention and Rehabilitation, Vol. 18, Núm. 3, pp. 518-525

  2. Treatment patterns in acute coronary syndrome patients in the United Kingdom undergoing PCI

    EuroIntervention, Vol. 6, Núm. 8, pp. 992-996

2010

  1. Treatment patterns in patients with acute coronary syndrome undergoing percutaneous coronary intervention

    Current Medical Research and Opinion, Vol. 26, Núm. 9, pp. 2193-2202

2008

  1. Desarrollo y validación de la versión corta de la Escala de Funcionamiento Social en esquizofrenia para su uso en la práctica clínica

    Actas Espanolas de Psiquiatria, Vol. 36, Núm. 2, pp. 102-110

2007

  1. Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms

    European Neuropsychopharmacology, Vol. 17, Núm. 11, pp. 725-734

  2. Safety and tolerability of olanzapine versus risperidone: A one-year randomized study in outpatients with schizophrenia with prominent negative symptoms

    Actas Espanolas de Psiquiatria, Vol. 35, Núm. 2, pp. 105-114

2006

  1. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia

    Journal of Clinical Psychopharmacology, Vol. 26, Núm. 3, pp. 238-249

  2. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 30, Núm. 8, pp. 1515-1522

  3. Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 Year follow-up naturalistic study

    Actas Espanolas de Psiquiatria, Vol. 34, Núm. 1, pp. 7-15

2005

  1. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: Results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, Núm. 6, pp. 972-982

2004

  1. Estudio observacional paneuropeo de la efectividad de la olanzapina frente a otros antipsicóticos (SOHO): Resultados basales de la muestra española

    Actas Espanolas de Psiquiatria, Vol. 32, Núm. 4, pp. 227-235

  2. Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: A naturalistic study

    European Psychiatry, Vol. 19, Núm. 6, pp. 358-365

2001

  1. Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: Results of an observational study (EFESO study)

    Actas Espanolas de Psiquiatria, Vol. 29, Núm. 1, pp. 25-32